Raymond James Financial’s IO Biotech IOBT Stock Holding History

Raymond James Financial’s Portfolio IOBT Stock Details IOBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,000	Closed	-$1.39K	–	5824
2025 Q2	$1.39K	Buy	+1,000	New	+$1.15K	﹤0.01%	6503

Other funds holding IOBT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Raymond James Financial's IOBT Position: Q3 2025 in Review

Raymond James Financial sold out of IO Biotech (IOBT) in Q3 2025, closing a stake of 1,000 shares — an estimated $1.39K sold.

Raymond James Financial first reported a position in IOBT in Q2 2025 and held it in 1 quarter. The position peaked at $1.39K in Q2 2025. 21 funds tracked by Wall St. Rank hold IOBT as of Q3 2025.

Raymond James Financial reported no remaining IO Biotech position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 1,000 IO Biotech shares in Q3 2025, an estimated $1.39K.
Raymond James Financial first reported a position in IO Biotech in Q2 2025 and held it in 1 quarter.
Raymond James Financial's IO Biotech position peaked at $1.39K in Q2 2025.
21 funds tracked by Wall St. Rank held IO Biotech as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.